search
Back to results

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

Primary Purpose

Asthma

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Fluticasone / Salmeterol
Placebo
Advair Diskus 100/50
Sponsored by
Roxane Laboratories
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and female subjects must be 12 years of age or older. Females must be of non-childbearing potential or if of childbearing potential, must commit to consistent use of a form of birth control which is medically effective.
  2. Be able to provide written informed consent or, in the case of adolescents, informed assent in addition to an informed consent form signed by the adolescent's parent(s) or legal guardian(s).
  3. Be current non-smokers and also may not have used tobacco products (e.g., cigarettes, cigars, pipe tobacco) within the year prior to Visit 1, and have 10 years or less (10 pack-years for cigarettes) of historical use.
  4. Have persistent asthma, as defined by the National Asthma Education and Prevention Program, for at least 12 weeks before Visit 1.
  5. The forced expiratory volume at one second ("FEV1") range required for enrollment is dependent on whether the subject is an adult or adolescent and whether he or she is currently treated with inhaled corticosteroids ("ICS") at Visit 1
  6. Demonstrate 15% or greater reversibility of FEV1 between 10 and 30 minutes following 360 µg of albuterol inhalation. NOTE: If the subject does not meet criterion 6 at Visit 1 (Day -14), this criterion must be met at Visit 2 (Day -1).
  7. Be able to discontinue controller asthma medication (including leukotriene modifiers ("LTM"), ICS and long acting β-agonists (LABAs)) during the Run-in Period and Treatment Period.
  8. Be able to replace current short-acting β-agonists (SABAs) with the study-supplied albuterol (or equivalent) rescue medication inhaler for use as needed for the duration of the study (subjects should be able to withhold all inhaled SABAs for a least 6 hours before lung function assessments during study visits).
  9. Be appropriately using 1 of the following asthma-treatment regimens and meet the associated criteria:

    • Low- to medium-dose ICS for at least 4 weeks before Visit 1, with or without an adjunctive asthma therapy (i.e., LABA, LTM, or theophylline). Both the ICS dose and overall daily asthma regimen must have been stable for the 4 weeks before Visit 1; or
    • Leukotriene modifier (such as montelukast, zafirlukast, or pranlukast) or theophylline as monotherapy at a stable dose for at least 4 weeks before Visit 1;or
    • Daily (or near daily) rescue medication (e.g., albuterol/ salbutamol or other inhaled SABA used to treat acute asthma) in the 4 weeks before Visit 1.
  10. Must not have been treated (for any reason) with oral or parenteral corticosteroids for at least 1 month before Visit 1 and must not have used oral SABAs for at least 12 hours before Visit 1 and for the remainder of the study. Routine use of oral/parenteral corticosteroids and oral SABAs is not allowed after Visit 1.
  11. Subjects may continue using short-acting forms of theophylline (withheld at least 12 hours before a site visit), twice daily controlled release forms of theophylline (withheld at least 24 hours before a site visit), and once daily controlled-release forms of theophylline (withheld at least 36 hours before a site visit).
  12. Be able to answer questions regarding asthma status and be able to document) device usage and asthma status on a twice daily basis.

    NOTE: Placebo inhaler use (i.e., compliance) must be at least 75% of the planned doses taken as assessed at Visit 2, for the subject to be considered eligible to continue in the study.

  13. Demonstrate proper use of metered dose inhaler ("MDI") and dry-powder inhaler devices.

Exclusion Criteria:

  1. Have an Asthma Control Questionnaire (ACQ) score of 3.0 or greater at Visit 1.
  2. Are unable to discontinue ICS, LABA, or LTM.
  3. Have a history of life-threatening asthma, defined as an asthma episode (at any time in the past) associated with any of the following: respiratory arrest or intubation, hypercapnia, hypoxic seizures, or syncopal episode.
  4. Have exercise-induced asthma as the only asthma-related diagnosis that does not require daily asthma control medicine.
  5. Have evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the subject at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
  6. Have current clinical evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease, or other respiratory abnormalities other than asthma.
  7. Have obstructive sleep apnea severe enough to require biphasic or continuous positive-airway pressure therapy, or likely to interfere with the assessment of asthma symptoms, in the investigator's judgment.
  8. Using medication with the potential to affect the course of asthma or interact with sympathomimetic amines (e.g., β blockers [including eye drops], oral decongestants, benzodiazepines, digitalis, phenothiazines, polycyclic antidepressants, monoamine oxidase inhibitors).
  9. Had a viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks before Visit 1 or have an infection during the Run-in Period.
  10. Participated in an interventional study or used any investigational drug for any disease within 30 days (or 4 half lives, if this is longer than 30 days) before Visit 1 before Visit 1.
  11. Used an anti-immunoglobulin E (e.g., omalizumab) or any other monoclonal antibody for any reason within 6 months before Visit 1.
  12. Are hypersensitive to any β2-agonist sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy or any component of these combination medications including severe milk protein hypersensitivity.
  13. Are exhibiting any factors (e.g., infirmity, disability, or geographic location, inability to follow instructions or study compliance requirements) that the investigator believes would likely limit the subject's compliance with the study protocol or scheduled site visits. This includes recent history of substance abuse or uncontrolled psychiatric or neurological behavior that would render the subject incapable of reliably following study requirements, in the judgment of the investigator.
  14. Have an affiliation with the participating site; in other words, subject may not be an immediate family member of any study site staff and may not be employed directly or indirectly by the study site.

Sites / Locations

  • Roxane Laboratories Research Site #30
  • Roxane Laboratories Research Site #46
  • Roxane Laboratories Research Site #1
  • Roxane Laboratories Research Site #13
  • Roxane Laboratories Research Site #84
  • Roxane Laboratories Research Site #72
  • Roxane Laboratories Research Site #67
  • Roxane Laboratories Research Site #4
  • Roxane Laboratories Research Site #64
  • Roxane Laboratories Research Site #3
  • Roxane Laboratories Research Site #70
  • Roxane Laboratories Research Site #92
  • Roxane Laboratories Research Site #38
  • Roxane Laboratories Research Site #91
  • Roxane Laboratories Research Site #59
  • Roxane Laboratories Research Site #16
  • Roxane Laboratories Research Site #90
  • Roxane Laboratories Research Site #6
  • Roxane Laboratories Research Site #78
  • Roxane Laboratories Research Site #98
  • Roxane Laboratories Research Site #53
  • Roxane Laboratories Research Site #93
  • Roxane Laboratories Research Site #28
  • Roxane Laboratories Research Site #60
  • Roxane Laboratories Research Site #33
  • Roxane Laboratories Research Site #43
  • Roxane Laboratories Research Site #63
  • Roxane Laboratories Research Site #21
  • Roxane Laboratories Research Site #50
  • Roxane Laboratories Research Site #11
  • Roxane Laboratories Research Site #66
  • Roxane Laboratories Research Site #83
  • Roxane Laboratories Research Site #8
  • Roxane Laboratories Research Site #23
  • Roxane Laboratories Research Site #86
  • Roxane Laboratories Research Site #89
  • Roxane Laboratories Research Site #20
  • Roxane Laboratories Research Site #68
  • Roxane Laboratories Research Site #80
  • Roxane Laboratories Research Site #54
  • Roxane Laboratories Research Site #12
  • Roxane Laboratories Research Site #74
  • Roxane Laboratories Research Site #35
  • Roxane Laboratories Research Site #17
  • Roxane Laboratories Research Site #94
  • Roxane Laboratories Research Site #34
  • Roxane Laboratories Research Site #51
  • Roxane Laboratories Research Site #79
  • Roxane Laboratories Research Site #47
  • Roxane Laboratories Research Site #100
  • Roxane Laboratories Research Site #62
  • Roxane Laboratories Research Site #52
  • Roxane Laboratories Research Site #71
  • Roxane Laboratories Research Site #96
  • Roxane Laboratories Research Site #81
  • Roxane Laboratories Research Site #56
  • Roxane Laboratories Research Site #55
  • Roxane Laboratories Research Site #97
  • Roxane Laboratories Research Site #5
  • Roxane Laboratories Research Site #85
  • Roxane Laboratories Research Site #32
  • Roxane Laboratories Research Site #25
  • Roxane Laboratories Research Site #36
  • Roxane Laboratories Research Site #57
  • Roxane Laboratories Research Site #10
  • Roxane Laboratories Research Site #65
  • Roxane Laboratories Research Site #7
  • Roxane Laboratories Research Site #2
  • Roxane Laboratories Research Site #41
  • Roxane Laboratories Research Site #45
  • Roxane Laboratories Research Site #31
  • Roxane Laboratories Research Site #95
  • Roxane Laboratories Research Site #24
  • Roxane Laboratories Research Site #61
  • Roxane Laboratories Research Site #73
  • Roxane Laboratories Research Site #14
  • Roxane Laboratories Research Site #15
  • Roxane Laboratories Research Site #37
  • Roxane Laboratories Research Site #40
  • Roxane Laboratories Research Site #58
  • Roxane Laboratories Research Site #26
  • Roxane Laboratories Research Site #99
  • Roxane Laboratories Research Site #69
  • Roxane Laboratories Research Site #22
  • Roxane Laboratories Research Site #19
  • Roxane Laboratories Research Site #27
  • Roxane Laboratories Research Site #75
  • Roxane Laboratories Research Site #49
  • Roxane Laboratories Research Site #44
  • Roxane Laboratories Research Site #77
  • Roxane Laboratories Research Site #87
  • Roxane Laboratories Research Site #29
  • Roxane Laboratories Research Site #48
  • Roxane Laboratories Research Site #42
  • Roxane Laboratories Research Site #39
  • Roxane Laboratories Research Site #9
  • Roxane Laboratories Research Site #88
  • Roxane Laboratories Research Site #18
  • Roxane Laboratories Research Site #76
  • Roxane Laboratories Research Site #82

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

Placebo Comparator

Arm Label

Fluticasone / Salmeterol

Advair Diskus 100/50

placebo inhaler

Arm Description

fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler ("LOMI") inhaler device twice a day by inhalation throughout the study

Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study

placebo inhaled powder twice a day by inhalation throughout the study

Outcomes

Primary Outcome Measures

Baseline-adjusted area under the serial FEV1-time curve from time 0 to 12 hours on the first day of the Treatment Period
Baseline-adjusted, pre-dose FEV1 on the last day of the Treatment Period

Secondary Outcome Measures

Adverse Events

Full Information

First Posted
January 5, 2016
Last Updated
January 19, 2018
Sponsor
Roxane Laboratories
Collaborators
Vectura Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT02649478
Brief Title
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
Official Title
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
August 2014 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
November 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Roxane Laboratories
Collaborators
Vectura Limited

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma
Detailed Description
The primary objective of this study is to evaluate the clinical bioequivalence of generic fluticasone propionate 100 µg and salmeterol xinafoate 50 µg inhalation powder (test) to Advair Diskus ("Advair") 100/50 (reference) for the treatment of asthma. The secondary objectives of the study are: To demonstrate statistical superiority of generic fluticasone propionate 100 µg and salmeterol xinafoate 50 µg inhalation powder to placebo. To demonstrate statistical superiority of Advair 100/50 to placebo. To investigate the safety and tolerability of fluticasone propionate 100 µg and salmeterol xinafoate 50 µg inhalation powder compared with Advair 100/50 in the target population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
1430 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fluticasone / Salmeterol
Arm Type
Experimental
Arm Description
fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler ("LOMI") inhaler device twice a day by inhalation throughout the study
Arm Title
Advair Diskus 100/50
Arm Type
Active Comparator
Arm Description
Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
Arm Title
placebo inhaler
Arm Type
Placebo Comparator
Arm Description
placebo inhaled powder twice a day by inhalation throughout the study
Intervention Type
Drug
Intervention Name(s)
Fluticasone / Salmeterol
Intervention Description
Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Type
Drug
Intervention Name(s)
Advair Diskus 100/50
Intervention Description
Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
Primary Outcome Measure Information:
Title
Baseline-adjusted area under the serial FEV1-time curve from time 0 to 12 hours on the first day of the Treatment Period
Time Frame
0-12 hours after dosing on Day 1
Title
Baseline-adjusted, pre-dose FEV1 on the last day of the Treatment Period
Time Frame
30 Days
Secondary Outcome Measure Information:
Title
Adverse Events
Time Frame
From Visit 1 (Day -28) until 30 days after the last dose of study drug

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female subjects must be 12 years of age or older. Females must be of non-childbearing potential or if of childbearing potential, must commit to consistent use of a form of birth control which is medically effective. Be able to provide written informed consent or, in the case of adolescents, informed assent in addition to an informed consent form signed by the adolescent's parent(s) or legal guardian(s). Be current non-smokers and also may not have used tobacco products (e.g., cigarettes, cigars, pipe tobacco) within the year prior to Visit 1, and have 10 years or less (10 pack-years for cigarettes) of historical use. Have persistent asthma, as defined by the National Asthma Education and Prevention Program, for at least 12 weeks before Visit 1. The forced expiratory volume at one second ("FEV1") range required for enrollment is dependent on whether the subject is an adult or adolescent and whether he or she is currently treated with inhaled corticosteroids ("ICS") at Visit 1 Demonstrate 15% or greater reversibility of FEV1 between 10 and 30 minutes following 360 µg of albuterol inhalation. NOTE: If the subject does not meet criterion 6 at Visit 1 (Day -14), this criterion must be met at Visit 2 (Day -1). Be able to discontinue controller asthma medication (including leukotriene modifiers ("LTM"), ICS and long acting β-agonists (LABAs)) during the Run-in Period and Treatment Period. Be able to replace current short-acting β-agonists (SABAs) with the study-supplied albuterol (or equivalent) rescue medication inhaler for use as needed for the duration of the study (subjects should be able to withhold all inhaled SABAs for a least 6 hours before lung function assessments during study visits). Be appropriately using 1 of the following asthma-treatment regimens and meet the associated criteria: Low- to medium-dose ICS for at least 4 weeks before Visit 1, with or without an adjunctive asthma therapy (i.e., LABA, LTM, or theophylline). Both the ICS dose and overall daily asthma regimen must have been stable for the 4 weeks before Visit 1; or Leukotriene modifier (such as montelukast, zafirlukast, or pranlukast) or theophylline as monotherapy at a stable dose for at least 4 weeks before Visit 1;or Daily (or near daily) rescue medication (e.g., albuterol/ salbutamol or other inhaled SABA used to treat acute asthma) in the 4 weeks before Visit 1. Must not have been treated (for any reason) with oral or parenteral corticosteroids for at least 1 month before Visit 1 and must not have used oral SABAs for at least 12 hours before Visit 1 and for the remainder of the study. Routine use of oral/parenteral corticosteroids and oral SABAs is not allowed after Visit 1. Subjects may continue using short-acting forms of theophylline (withheld at least 12 hours before a site visit), twice daily controlled release forms of theophylline (withheld at least 24 hours before a site visit), and once daily controlled-release forms of theophylline (withheld at least 36 hours before a site visit). Be able to answer questions regarding asthma status and be able to document) device usage and asthma status on a twice daily basis. NOTE: Placebo inhaler use (i.e., compliance) must be at least 75% of the planned doses taken as assessed at Visit 2, for the subject to be considered eligible to continue in the study. Demonstrate proper use of metered dose inhaler ("MDI") and dry-powder inhaler devices. Exclusion Criteria: Have an Asthma Control Questionnaire (ACQ) score of 3.0 or greater at Visit 1. Are unable to discontinue ICS, LABA, or LTM. Have a history of life-threatening asthma, defined as an asthma episode (at any time in the past) associated with any of the following: respiratory arrest or intubation, hypercapnia, hypoxic seizures, or syncopal episode. Have exercise-induced asthma as the only asthma-related diagnosis that does not require daily asthma control medicine. Have evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the subject at risk through study participation, or would affect the study analyses if the disease exacerbated during the study. Have current clinical evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, chronic obstructive pulmonary disease, or other respiratory abnormalities other than asthma. Have obstructive sleep apnea severe enough to require biphasic or continuous positive-airway pressure therapy, or likely to interfere with the assessment of asthma symptoms, in the investigator's judgment. Using medication with the potential to affect the course of asthma or interact with sympathomimetic amines (e.g., β blockers [including eye drops], oral decongestants, benzodiazepines, digitalis, phenothiazines, polycyclic antidepressants, monoamine oxidase inhibitors). Had a viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks before Visit 1 or have an infection during the Run-in Period. Participated in an interventional study or used any investigational drug for any disease within 30 days (or 4 half lives, if this is longer than 30 days) before Visit 1 before Visit 1. Used an anti-immunoglobulin E (e.g., omalizumab) or any other monoclonal antibody for any reason within 6 months before Visit 1. Are hypersensitive to any β2-agonist sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy or any component of these combination medications including severe milk protein hypersensitivity. Are exhibiting any factors (e.g., infirmity, disability, or geographic location, inability to follow instructions or study compliance requirements) that the investigator believes would likely limit the subject's compliance with the study protocol or scheduled site visits. This includes recent history of substance abuse or uncontrolled psychiatric or neurological behavior that would render the subject incapable of reliably following study requirements, in the judgment of the investigator. Have an affiliation with the participating site; in other words, subject may not be an immediate family member of any study site staff and may not be employed directly or indirectly by the study site.
Facility Information:
Facility Name
Roxane Laboratories Research Site #30
City
Glendale
State/Province
Arizona
ZIP/Postal Code
85306
Country
United States
Facility Name
Roxane Laboratories Research Site #46
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85018
Country
United States
Facility Name
Roxane Laboratories Research Site #1
City
Surprise
State/Province
Arizona
ZIP/Postal Code
85374
Country
United States
Facility Name
Roxane Laboratories Research Site #13
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85283
Country
United States
Facility Name
Roxane Laboratories Research Site #84
City
Bakersfield
State/Province
California
ZIP/Postal Code
93301
Country
United States
Facility Name
Roxane Laboratories Research Site #72
City
Costa Mesa
State/Province
California
ZIP/Postal Code
92626
Country
United States
Facility Name
Roxane Laboratories Research Site #67
City
Encinitas
State/Province
California
ZIP/Postal Code
92024
Country
United States
Facility Name
Roxane Laboratories Research Site #4
City
Fountain Valley
State/Province
California
ZIP/Postal Code
90708
Country
United States
Facility Name
Roxane Laboratories Research Site #64
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
Facility Name
Roxane Laboratories Research Site #3
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92647
Country
United States
Facility Name
Roxane Laboratories Research Site #70
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92647
Country
United States
Facility Name
Roxane Laboratories Research Site #92
City
Huntington Beach
State/Province
California
ZIP/Postal Code
92647
Country
United States
Facility Name
Roxane Laboratories Research Site #38
City
Irvine
State/Province
California
ZIP/Postal Code
92614
Country
United States
Facility Name
Roxane Laboratories Research Site #91
City
Lincoln
State/Province
California
ZIP/Postal Code
95648
Country
United States
Facility Name
Roxane Laboratories Research Site #59
City
Los Angeles
State/Province
California
ZIP/Postal Code
90017
Country
United States
Facility Name
Roxane Laboratories Research Site #16
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Facility Name
Roxane Laboratories Research Site #90
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Roxane Laboratories Research Site #6
City
Mission Viejo
State/Province
California
ZIP/Postal Code
92691
Country
United States
Facility Name
Roxane Laboratories Research Site #78
City
Rolling Hills Estates
State/Province
California
ZIP/Postal Code
90274
Country
United States
Facility Name
Roxane Laboratories Research Site #98
City
Sacramento
State/Province
California
ZIP/Postal Code
95821
Country
United States
Facility Name
Roxane Laboratories Research Site #53
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
Roxane Laboratories Research Site #93
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Roxane Laboratories Research Site #28
City
San Jose
State/Province
California
ZIP/Postal Code
95117
Country
United States
Facility Name
Roxane Laboratories Research Site #60
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Roxane Laboratories Research Site #33
City
Centennial
State/Province
Colorado
ZIP/Postal Code
80112
Country
United States
Facility Name
Roxane Laboratories Research Site #43
City
Denver
State/Province
Colorado
ZIP/Postal Code
80246
Country
United States
Facility Name
Roxane Laboratories Research Site #63
City
Denver
State/Province
Colorado
ZIP/Postal Code
80246
Country
United States
Facility Name
Roxane Laboratories Research Site #21
City
Wheat Ridge
State/Province
Colorado
ZIP/Postal Code
80033
Country
United States
Facility Name
Roxane Laboratories Research Site #50
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33012
Country
United States
Facility Name
Roxane Laboratories Research Site #11
City
Hialeah
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
Facility Name
Roxane Laboratories Research Site #66
City
Homestead
State/Province
Florida
ZIP/Postal Code
33030
Country
United States
Facility Name
Roxane Laboratories Research Site #83
City
Jupiter
State/Province
Florida
ZIP/Postal Code
33458
Country
United States
Facility Name
Roxane Laboratories Research Site #8
City
Miami
State/Province
Florida
ZIP/Postal Code
33126
Country
United States
Facility Name
Roxane Laboratories Research Site #23
City
Miami
State/Province
Florida
ZIP/Postal Code
33135
Country
United States
Facility Name
Roxane Laboratories Research Site #86
City
Miami
State/Province
Florida
ZIP/Postal Code
33144
Country
United States
Facility Name
Roxane Laboratories Research Site #89
City
Miami
State/Province
Florida
ZIP/Postal Code
33144
Country
United States
Facility Name
Roxane Laboratories Research Site #20
City
Miami
State/Province
Florida
ZIP/Postal Code
33155
Country
United States
Facility Name
Roxane Laboratories Research Site #68
City
Miami
State/Province
Florida
ZIP/Postal Code
33165
Country
United States
Facility Name
Roxane Laboratories Research Site #80
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
Facility Name
Roxane Laboratories Research Site #54
City
Miami
State/Province
Florida
ZIP/Postal Code
33174
Country
United States
Facility Name
Roxane Laboratories Research Site #12
City
Miami
State/Province
Florida
ZIP/Postal Code
33185
Country
United States
Facility Name
Roxane Laboratories Research Site #74
City
North Miami Beach
State/Province
Florida
ZIP/Postal Code
33162
Country
United States
Facility Name
Roxane Laboratories Research Site #35
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
Roxane Laboratories Research Site #17
City
Orlando
State/Province
Florida
ZIP/Postal Code
32825
Country
United States
Facility Name
Roxane Laboratories Research Site #94
City
Port Orange
State/Province
Florida
ZIP/Postal Code
32127
Country
United States
Facility Name
Roxane Laboratories Research Site #34
City
Lilburn
State/Province
Georgia
ZIP/Postal Code
30047
Country
United States
Facility Name
Roxane Laboratories Research Site #51
City
Rincon
State/Province
Georgia
ZIP/Postal Code
31326
Country
United States
Facility Name
Roxane Laboratories Research Site #79
City
Normal
State/Province
Illinois
ZIP/Postal Code
61761
Country
United States
Facility Name
Roxane Laboratories Research Site #47
City
River Forest
State/Province
Illinois
ZIP/Postal Code
60305
Country
United States
Facility Name
Roxane Laboratories Research Site #100
City
Brownsburg
State/Province
Indiana
ZIP/Postal Code
46112
Country
United States
Facility Name
Roxane Laboratories Research Site #62
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21225
Country
United States
Facility Name
Roxane Laboratories Research Site #52
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21236
Country
United States
Facility Name
Roxane Laboratories Research Site #71
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20814
Country
United States
Facility Name
Roxane Laboratories Research Site #96
City
Silver Spring
State/Province
Maryland
ZIP/Postal Code
20902
Country
United States
Facility Name
Roxane Laboratories Research Site #81
City
Fall River
State/Province
Massachusetts
ZIP/Postal Code
02720
Country
United States
Facility Name
Roxane Laboratories Research Site #56
City
North Dartmouth
State/Province
Massachusetts
ZIP/Postal Code
02747
Country
United States
Facility Name
Roxane Laboratories Research Site #55
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48106
Country
United States
Facility Name
Roxane Laboratories Research Site #97
City
Chelsea
State/Province
Michigan
ZIP/Postal Code
48118
Country
United States
Facility Name
Roxane Laboratories Research Site #5
City
Plymouth
State/Province
Minnesota
ZIP/Postal Code
55441
Country
United States
Facility Name
Roxane Laboratories Research Site #85
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Roxane Laboratories Research Site #32
City
Bellevue
State/Province
Nebraska
ZIP/Postal Code
68005
Country
United States
Facility Name
Roxane Laboratories Research Site #25
City
Bellevue
State/Province
Nebraska
ZIP/Postal Code
68123
Country
United States
Facility Name
Roxane Laboratories Research Site #36
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68114
Country
United States
Facility Name
Roxane Laboratories Research Site #57
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89119
Country
United States
Facility Name
Roxane Laboratories Research Site #10
City
Atco
State/Province
New Jersey
ZIP/Postal Code
08004
Country
United States
Facility Name
Roxane Laboratories Research Site #65
City
Skillman
State/Province
New Jersey
ZIP/Postal Code
08558
Country
United States
Facility Name
Roxane Laboratories Research Site #7
City
New York
State/Province
New York
ZIP/Postal Code
10018
Country
United States
Facility Name
Roxane Laboratories Research Site #2
City
New York
State/Province
New York
ZIP/Postal Code
10019
Country
United States
Facility Name
Roxane Laboratories Research Site #41
City
Clemmons
State/Province
North Carolina
ZIP/Postal Code
27012
Country
United States
Facility Name
Roxane Laboratories Research Site #45
City
Raleigh
State/Province
North Carolina
ZIP/Postal Code
27607
Country
United States
Facility Name
Roxane Laboratories Research Site #31
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Facility Name
Roxane Laboratories Research Site #95
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43214
Country
United States
Facility Name
Roxane Laboratories Research Site #24
City
Hilliard
State/Province
Ohio
ZIP/Postal Code
43026
Country
United States
Facility Name
Roxane Laboratories Research Site #61
City
Middleburg Heights
State/Province
Ohio
ZIP/Postal Code
44130
Country
United States
Facility Name
Roxane Laboratories Research Site #73
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43617
Country
United States
Facility Name
Roxane Laboratories Research Site #14
City
Edmond
State/Province
Oklahoma
ZIP/Postal Code
73034
Country
United States
Facility Name
Roxane Laboratories Research Site #15
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73103
Country
United States
Facility Name
Roxane Laboratories Research Site #37
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States
Facility Name
Roxane Laboratories Research Site #40
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
Facility Name
Roxane Laboratories Research Site #58
City
Portland
State/Province
Oregon
ZIP/Postal Code
97202
Country
United States
Facility Name
Roxane Laboratories Research Site #26
City
Warwick
State/Province
Rhode Island
ZIP/Postal Code
02886
Country
United States
Facility Name
Roxane Laboratories Research Site #99
City
Warwick
State/Province
Rhode Island
ZIP/Postal Code
02886
Country
United States
Facility Name
Roxane Laboratories Research Site #69
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
Facility Name
Roxane Laboratories Research Site #22
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29303
Country
United States
Facility Name
Roxane Laboratories Research Site #19
City
Smyrna
State/Province
Tennessee
ZIP/Postal Code
37167
Country
United States
Facility Name
Roxane Laboratories Research Site #27
City
Boerne
State/Province
Texas
ZIP/Postal Code
78006
Country
United States
Facility Name
Roxane Laboratories Research Site #75
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Roxane Laboratories Research Site #49
City
El Paso
State/Province
Texas
ZIP/Postal Code
79903
Country
United States
Facility Name
Roxane Laboratories Research Site #44
City
Houston
State/Province
Texas
ZIP/Postal Code
77043
Country
United States
Facility Name
Roxane Laboratories Research Site #77
City
Lewisville
State/Province
Texas
ZIP/Postal Code
75067
Country
United States
Facility Name
Roxane Laboratories Research Site #87
City
Plano
State/Province
Texas
ZIP/Postal Code
75093
Country
United States
Facility Name
Roxane Laboratories Research Site #29
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78251
Country
United States
Facility Name
Roxane Laboratories Research Site #48
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
Roxane Laboratories Research Site #42
City
West Jordan
State/Province
Utah
ZIP/Postal Code
84088
Country
United States
Facility Name
Roxane Laboratories Research Site #39
City
South Burlington
State/Province
Vermont
ZIP/Postal Code
05403
Country
United States
Facility Name
Roxane Laboratories Research Site #9
City
Henrico
State/Province
Virginia
ZIP/Postal Code
23233
Country
United States
Facility Name
Roxane Laboratories Research Site #88
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23220
Country
United States
Facility Name
Roxane Laboratories Research Site #18
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23235
Country
United States
Facility Name
Roxane Laboratories Research Site #76
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
Roxane Laboratories Research Site #82
City
Greenfield
State/Province
Wisconsin
ZIP/Postal Code
53228
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

We'll reach out to this number within 24 hrs